Hypoparathyroidism in Special Populations: Pediatric, Geriatric, and Comorbid Patients

For pediatric patients, Dr. Ferenczi explains that the key adaptations involve growth considerations, dosing logistics, and a more conservative stance toward PTH therapy. Active vitamin D—specifically calcitriol—is the treatment backbone, bypassing the renal 1-alpha-hydroxylase step that is impaired by PTH deficiency. Calcium is weaned to the minimum needed to maintain low-normal serum levels, with divided doses under 500 mg at mealtimes to optimize absorption. Neonatal hypocalcemia may be managed with low-phosphate formulas to optimize the calcium-to-phosphate ratio. PTH analogs are not standard of care in children, are currently only adult-indicated, and pediatric registration studies are just beginning. She highlights that non-surgical genetic causes—APS1, DiGeorge syndrome, ADH1—predominate in pediatrics and require syndrome-specific surveillance for associated complications such as deafness, cardiac disease, and immune deficiency.

For geriatric and comorbid patients, Dr. Ferenczi notes that management divergences are driven largely by comorbidity burden rather than age alone. Declining GFR from CKD narrows the already tight therapeutic window by impairing vitamin D activation and phosphate clearance, raising calcium-phosphate product risk, and creating a strong rationale for PTH replacement. Osteoporosis may benefit from PTH therapy's bone anabolic properties, though bisphosphonates and denosumab can precipitate significant hypocalcemia and require careful monitoring. Cardiovascular disease and polypharmacy in older patients increase the risk of QT prolongation and arrhythmias from calcium swings. Patients with malabsorption—from bariatric surgery, IBD, or proton pump inhibitor use—should receive calcium citrate over carbonate and represent a recognized trigger to consider PTH replacement.

In the next episode, "Unmet Needs in the Hypoparathyroidism Treatment Landscape," Dr. Khosravi surveys the most significant remaining unmet needs in hypoparathyroidism—from the limitations of conventional and PTH replacement therapy to data gaps in special populations, skeletal outcomes, and the ongoing burden experienced by patients.